

## 研究成果の刊行に関する一覧表

## 雑誌

- 1) Mizukami T, Shiraishi K, Shimada Y, Ogiwara H, Tsuta K, Ichikawa H, Sakamoto H, Kato M, Shibata T, Nakano T, Kohno T. Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma. *J Thoracic Oncol* 2014, in press.
- 2) Nakaoku T, Tsuta K, Ichikawa H, Shiraishi K, Sakamoto H, Enari M, Furuta K, Shimada Y, Ogiwara H, Watanabe SI, Nokihara H, Yasuda K, Hiramoto M, Nammo T, Ishigame T, Schetter AJ, Okayama H, Harris CC, Kim YH, Mishima M, Yokota J, Yoshida T, Kohno T. Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma. *Clin Cancer Res* 2014, in press.
- 3) Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, Saez C, Iwakawa R, Villanueva A, Montuenga LM, Kohno T, Yokota J, Sanchez-Cespedes M. MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1. *Cancer Discov* 2014;4:292-303.
- 4) Kohno T, Tsuta K, Tsuchihara K, Nakaoku T, Yoh K, Goto K. RET fusion gene: translation to personalized lung cancer therapy. *Cancer Sci* 2013;104:1396-400.
- 5) Oike T, Ogiwara H, Tominaga Y, Ito K, Ando O, Tsuta K, Mizukami T, Shimada Y, Isomura H, Komachi M, Furuta K, Watanabe S, Nakano T, Yokota J, Kohno T. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. *Cancer Res* 2013;73:5508-18.
- 6) Akagi I, Okayama H, Schetter AJ, Robles AI, Kohno T, Bowman ED, Kazandjian D, Welsh JA, Oue N, Saito M, Miyashita M, Uchida E, Takizawa T, Takenoshita S, Skaug V, Mollerup S, Haugen A, Yokota J, Harris CC. Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma. *Cancer Res* 2013;73:3821-32.
- 7) Iwakawa R, Takenaka M, Kohno T, Shimada Y, Totoki Y, Shibata T, Tsuta K, Nishikawa R, Noguchi M, Sato-Otsubo A, Ogawa S, Yokota J. Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. *Genes Chromosomes Cancer* 2013;52:802-16.
- 8) Yoshida A, Kohno T, Tsuta K, Wakai S, Shimada Y, Arai Y, Asamura H, Furuta K, Shibata T, Tsuda H. ROS1-Rearranged Lung Cancer: Clinicopathologic and Molecular Study of 15 Surgical Cases. *Am J Surg Pathol* 2013;37:554-62.
- 9) Otsubo C, Otomo R, Miyazaki M, Matsushima-Hibiya Y, Kohno T, Iwakawa R, Takeshita F, Okayama H, Ichikawa H, Saya H, Kiyono T, Ochiya T, Tashiro F, Nakagama H, Yokota J, Enari M. TSPAN2 Is Involved in Cell Invasion and Motility during Lung Cancer Progression. *Cell Rep* 2014 Apr 9. [Epub ahead of print]
- 10) Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, Gunji T, Ohta H, Okamoto H, Sonoda H, Watanabe M, Nakagama H, Yokota J, Kohno T, Tsuchiya N. Circulating Exosomal microRNAs as Biomarkers of Colon Cancer. *PLoS One* 2014;9:e92921.
- 11) Ragin C, Obikoya-Malomo M, Kim S, Chen Z, Flores-Obando R, Gibbs D, Koriyama C, Aguayo F, Koshiol J, Caporaso NE, Carpagnano GE, Ciotti M, Dosaka-Akita H, Fukayama M, Goto A, Spandidos DA, Gorgoulis V, Heideman DA, van Boerdonk RA, Hiroshima K, Iwakawa R, Kastrinakis NG, Kinoshita I, Akiba S, Landi MT, Eugene Liu H, Wang JL, Mehra R, Khuri FR, Lim WT, Owonikoko TK, Ramalingam S, Sarchianaki E, Syrjanen K, Tsao MS, Sykes J, Hee SW, Yokota J, Zaravinos A, Taioli E. HPV-associated lung cancers: an international pooled analysis. *Carcinogenesis* 2014 Feb 26. [Epub ahead of print]
- 12) Murata Y, Minami Y, Iwakawa R, Yokota J, Usui S, Tsuta K, Shiraishi K, Sakashita S, Satomi K, Iijima T, Noguchi M. ECT2 amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinoma. *Cancer Sci* 2014;105:490-7.
- 13) Oike T, Ogiwara H, Nakano T, Yokota J, Kohno T. Inactivating mutations in SWI/SNF chromatin remodeling genes in human cancer. *Jpn J Clin Oncol* 2013;43:849-55.
- 14) Ohata H, Miyazaki M, Otomo R, Matsushima-Hibiya Y, Otsubo C, Nagase T, Arakawa H, Yokota J, Nakagama H, Taya Y, Enari M. NuMA Is Required for the Selective Induction of p53-Target Genes. *Mol Cell Biol* 2013;33:2447-57.
- 15) Ui A, Ogiwara H, Nakajima S, Kanno S, Watanabe R, Harata M, Okayama H, Harris CC, Yokota J, Yasui A, Kohno T. Possible involvement of LKB1-AMPK signaling in non-homologous end joining. *Oncogene* 2014;33:1640-8.
- 16) Akca H, Demiray A, Yaren A, Bir F, Koseler A, Iwakawa R, Bagci G, Yokota J. Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer. *Cancer Genet*

2013;206:73-80.

- 17) Travis WD, Brambilla E, Noguchi M, Nicholson A, Geisinger K, Yatabe Y, Ishikawa Y, Wistuba I, Flieder DB, Franklin W, Gazdar A, Hasleton PS, Henderson DW, Kerr KM, Nakatani Y, Petersen I, Roggli V, Thunnissen E, Tsao M. Diagnosis of Lung Adenocarcinoma in Resected Specimens: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. *Arch Pathol Lab Med* 2013;137:685-705.
- 18) Travis WD, Brambilla E, Noguchi M, Nicholson A, Geisinger K, Yatabe Y, Ishikawa Y, Wistuba I, Flieder DB, Franklin W, Gazdar A, Hasleton PS, Henderson DW, Kerr KM, Petersen I, Roggli V, Thunnissen E, Tsao M. Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. *Arch Pathol Lab Med* 2013;137:668-84.
- 19) Nakazato Y, Maeshima MA, Ishikawa Y, Yatabe Y, Fukuoka J, Yokose T, Tomita Y, Minami Y, Asamura Y, Tachibana K, Goya T, Noguchi M. Inter observer agreement in the nuclear grading of primary pulmonary adenocarcinoma. *J Thorac Onco* 2013;8:736-43.
- 20) Kawamura T, Usui J, Kaseda K, Takeda K, Ebihara I, Ishizu T, Iitsuka T, Sakai K, Takemura K, Kobayashi M, Koyama A, Kanemoto K, Sumazaki R, Uesugi N, Noguchi M, Nagata M, Suka M, Yamagata K. Primary membranoproliferative glomerulonephritis on the decline: decreased rate from the 1970s to the 2000s Japan. *Clin Exp Nephrol* 2013;17:248-54.
- 21) Usui S, Minami Y, Shiosawa T, Iyama S, Sato Y, Noguchi M. Differences in the prognostic implications of vascular invasion between lung adenocarcinoma and squamous cell carcinoma. *Lung Cancer* 2013;82:407-12.
- 22) Thunnissen E, Beliën JA, Kerr KM, Chung JH, Flieder DB, Noguchi M, Yatabe Y, Hwang DM, Lely RJ, Hartemink KJ, Meijer-Jorna LB, Ysao MS. In compressed lung tissue microscopic sections of adenocarcinoma in situ may mimic papillary adenocarcinoma. *Arch Pathol Lab Med* 2013;137:1792-7.
- 23) Yoshida K, Toki T, Okuno Y, Kanezaki R, Shiraishi Y, Sato-Otsubo A, Sanada M, Park MJ, Terui K, Suzuki H, Kon A, Nagata Y, Sato Y, Wang R, Shiba N, Chiba K, Tanaka H, Hama A, Muramatsu H, Hasegawa D, Nakamura K, Kanegane H, Tsukamoto K, Adachi S, Kawakami K, Kato K, Nishimura R, Izraeli S, Hayashi Y, Miyano S, Kojima S, Ito E, Ogawa S. The landscape of somatic mutations in Down syndrome-related myeloid disorders. *Nat Genet* 2013;45:1293-9.
- 24) Yoshida K, Sanada M, Ogawa S. Deep sequencing in cancer research. *Jpn J Clin Oncol* 2013;43:110-5.
- 25) Shiraishi Y, Sato Y, Chiba K, Okuno Y, Nagata Y, Yoshida K, Shiba N, Hayashi Y, Kume H, Homma Y, Sanada M, Ogawa S, Miyano S. An empirical Bayesian framework for somatic mutation detection from cancer genome sequencing data. *Nucleic Acids Res* 2013;41:e89.
- 26) Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki H, Nagata Y, Yoshida K, Kon A, Suzuki Y, Chiba K, Tanaka H, Niida A, Fujimoto A, Tsunoda T, Morikawa T, Maeda D, Kume H, Sugano S, Fukayama M, Aburatani H, Sanada M, Miyano S, Homma Y, Ogawa S. Integrated molecular analysis of clear-cell renal cell carcinoma. *Nat Genet* 2013;45:860-7.
- 27) Sakaguchi H, Okuno Y, Muramatsu H, Yoshida K, Shiraishi Y, Takahashi M, Kon A, Sanada M, Chiba K, Tanaka H, Makishima H, Wang X, Xu Y, Doisaki S, Hama A, Nakanishi K, Takahashi Y, Yoshida N, Maciejewski JP, Miyano S, Ogawa S, Kojima S. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. *Nat Genet* 2013;45:937-41.
- 28) Saida S, Watanabe KI, Sato-Otsubo A, Terui K, Yoshida K, Okuno Y, Toki T, Wang R, Shiraishi Y, Miyano S, Kato I, Morishima T, Fujino H, Umeda K, Hiramatsu H, Adachi S, Ito E, Ogawa S, Ito M, Nakahata T, Heike T. Clonal selection in xenografted TAM recapitulates the evolutionary process of myeloid leukemia in Down syndrome. *Blood* 2013;121:4377-87.
- 29) Nishimura R, Takita J, Sato-Otsubo A, Kato M, Koh K, Hanada R, Tanaka Y, Kato K, Maeda D, Fukayama M, Sanada M, Hayashi Y, Ogawa S. Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array. *Cancer Sci* 2013;104:856-64.
- 30) Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y, Ng KP, Gudmundsson KO, Vishwakarma BA, Jerez A, Gomez-Segui I, Takahashi M, Shiraishi Y, Nagata Y, Guinta K, Mori H, Sekeres MA, Chiba K, Tanaka H, Muramatsu H, Sakaguchi H, Paquette RL, McDevitt MA, Kojima S, Sauntharajah Y, Miyano S, Shih LY, Du Y, Ogawa S, Maciejewski JP. Somatic SETBP1 mutations in myeloid malignancies. *Nat Genet* 2013;45:942-6.
- 31) Kunishima S, Okuno Y, Yoshida K, Shiraishi Y, Sanada M, Muramatsu H, Chiba K, Tanaka H, Miyazaki K, Sakai M, Ohtake M, Kobayashi R, Iguchi A, Niimi G, Otsu M, Takahashi Y, Miyano S, Saito H, Kojima S, Ogawa S. ACTN1 Mutations Cause Congenital Macrothrombocytopenia. *Am J Hum Genet* 2013;92:431-8.

- 32) Kon A, Shih LY, Minamino M, Sanada M, Shiraishi Y, Nagata Y, Yoshida K, Okuno Y, Bando M, Nakato R, Ishikawa S, Sato-Otsubo A, Nagae G, Nishimoto A, Haferlach C, Nowak D, Sato Y, Alpermann T, Nagasaki M, Shimamura T, Tanaka H, Chiba K, Yamamoto R, Yamaguchi T, Otsu M, Obara N, Sakata-Yanagimoto M, Nakamaki T, Ishiyama K, Nolte F, Hofmann WK, Miyawaki S, Chiba S, Mori H, Nakauchi H, Koeffler HP, Aburatani H, Haferlach T, Shirahige K, Miyano S, Ogawa S. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. *Nat Genet* 2013;45:1232-7.
- 33) Nakahata S, Ichikawa T, Maneesaay P, Saito Y, Nagai K, Tamura T, Manachai N, Yamakawa N, Hamasaki M, Kitabayashi I, Arai Y, Kanai Y, Taki T, Abe T, Kiyonari H, Shimoda K, Ohshima K, Horii A, Shima H, Taniwaki M, Yamaguchi R, Morishita K. Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers. *Nature Comm* 2014;5:3393.
- 34) Kai H, Akamatsu E, Torii E, Kodama H, Yukizaki C, Akagi I, Ino H, Sakakibara Y, Suiko M, Yamamoto I, Okayama A, Morishita K, Kataoka H, Matsuno K: Identification of a bioactive compound against adult T-cell leukemia from bitter melon seeds. *Plants* 2014;3:18-26.
- 35) Yamamura A, Miura K, Karasawa H, Morishita K, Abe K, Mizuguchi Y, Saiki Y, Fukushige S, Kaneko N, Sase T, Nagase H, Sunamura M, Motoi F, Egawa S, Shibata C, Unno M, Sasaki I, Horii A. Suppressed expression of NDRG2 correlates with poor prognosis in pancreatic cancer. *Biochem Biophys Res Commun* 2013;441:102-7.
- 36) Ikebe E, Kawaguchi A, Tezuka K, Taguchi S, Hirose S, Matsumoto T, Mitsui T, Senba K, Nishizono A, Hori M, Hasegawa H, Yamada Y, Ueno T, Tanaka Y, Sawa H, Hall W, Minami Y, Jeang KT, Ogata M, Morishita K, Hasegawa H, Fujisawa J, Iha H. Oral administration of an HSP90 inhibitor, 17-DMAG, intervenes tumor-cell infiltration into multiple organs and improves survival period for ATL model mice. *Blood Cancer J* 2013;3:e132.
- 37) Sugie S, Mukai S, Tsukino H, Toda Y, Yamauchi T, Nishikata I, Kuroda Y, Morishita K, Kamoto T. Increased plasma caveolin-1 levels are associated with progression of prostate cancer among Japanese men. *Anticancer Res* 2013;33:1893-7.
- 38) Yamasaki M, Mine Y, Nishimura M, Fujita S, Sakakibara Y, Suiko M, Morishita K, Nishiyama K. Genistein induces apoptotic cell death associated with inhibition of the NF- $\kappa$ B pathway in adult T-cell leukemia cells. *Cell Biol Int* 2013;37:742-7.
- 39) Saito Y, Kaneda K, Suekane A, Ichihara E, Nakahata S, Yamakawa N, Nagai K, Mizuno N, Kogawa K, Miura I, Itoh H, Morishita K. Maintenance of the hematopoietic stem cell pool in bone marrow niches by EVI1-regulated GPR56. *Leukemia* 2013;27:1637-49.
- 40) Hosoda F, Arai Y, Okada N, Shimizu H, Miyamoto M, Kitagawa N, Katai H, Taniguchi H, Yanagihara K, Imoto I, Inazawa J, Ohki M, Shibata T. Integrated Genomic and Functional Analyses Reveal Glyoxalase I as a Novel Metabolic Oncogene in Human Gastric Cancer. *Oncogene* 2013, in press.
- 41) Okusaka T, Ojima H, Morizane C, Ikeda M, Shibata T. Emerging drugs for biliary cancer. *Expert Opin Emerg Drugs*. 2013 Dec 20. [Epub ahead of print]
- 42) Noro R, Honda K, Tsuta K, Ishii G, Maeshima AM, Miura N, Furuta K, Shibata T, Tsuda H, Ochiai A, Sakuma T, Nishijima N, Gemma A, Asamura H, Nagai K, Yamada T. Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification. *Ann Oncol* 2013;24:2594-600.
- 43) Yoshida A, Shibata T, Tsuta K, Watanabe S, Tsuda H. Inflammatory myofibroblastic tumor of the lung with a novel isoform of PPF1B1-ALK fusion gene. *Histopathology* 2013;63:881-3.
- 44) Murakami S, Chisima S, Uemoto H, Sakamoto E, Sato T, Kurabe N, Kawasaki Y, Shibata T, Akiyama H, Tashiro F. The male-specific factor Sry harbors an oncogenic function. *Oncogene* 2013 Jul 29. [Epub ahead of print]
- 45) Nakamura H, Tsuta K, Yoshida A, Shibata T, Wakai S, Asamura H, Furuta K, Tsuda H. Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma. *J Clin Pathol*. 2013, 66:705-7
- 46) Suzuki T, Shibata T, Takaya K, Shiraishi K, Kohno T, Kunitoh H, Tsuta K, Furuta K, Goto K, Hosoda F, Sakamoto H, Motohashi H, Yamamoto M. Regulatory Nexus of Synthesis and Degradation Deciphers Cellular Nrf2 Expression Levels. *Mol Cell Biol* 2013;33:2402-12.
- 47) Suzuki M, Makinoshima H, Matsumoto S, Suzuki A, Mimaki S, Matsushima K, Yoh K, Goto K, Suzuki Y, Ishii G, Ochiai A, Tsuta K, Shibata T, Kohno T, Esumi H, Tsuchihara K. Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo. *Cancer Sci* 2013;104:896-903.
- 48) Kitagawa N, Ojima H, Shirakihara T, Shimizu H, Kokubu A, Urushidate T, Totoki Y, Kosuge T, Miyagawa S, Shibata T. Downregulation of the microRNA biogenesis components and its association with poor

prognosis in hepatocellular carcinoma. *Cancer Sci* 2013;104:543-51.

- 49) Gailhouste L, Gomez-Santos L, Kitagawa N, Kawaharada K, Thirion M, Kosaka N, Takahashi R, Shibata T, Miyajima A, Ochiya T. MiR-148a plays a pivotal role in the liver by promoting the hepatospecific phenotype and suppressing the invasiveness of transformed cells. *Hepatology* 2013;58:1153-65.
- 50) Arai Y, Totoki Y, Takahashi H, Nakamura H, Hama N, Kohno T, Tsuta K, Yoshida A, Asamura H, Mutoh M, Hosoda F, Tsuda H, Shibata T. Mouse Model for ROS1-Rearranged Lung Cancer. *PLoS One* 2013;8:e56010.
- 51) Uno M, Saitoh Y, Mochida K, Tsuruyama E, Kiyono T, Imoto I, Inazawa J, Yuasa Y, Kubota T, Yamaoka S. NF- $\kappa$ B Inducing Kinase, a Central Signaling Component of the Non-Canonical Pathway of NF- $\kappa$ B, Contributes to Ovarian Cancer Progression. *PLoS One* 2014;9:e88347.
- 52) Takemura K, Kawachi H, Eishi Y, Kitagaki K, Negi M, Kobayashi M, Uchida K, Inoue J, Inazawa J, Kawano T, Board PG.  $\alpha$ -Glutamylcyclotransferase as a novel immunohistochemical biomarker for the malignancy of esophageal squamous tumors. *Hum Pathol* 2014;45:331-41.
- 53) Dobashi Y, Sato E, Oda Y, Inazawa J, Ooi A: Significance of Akt activation and AKT gene increases in soft tissue tumors. *Hum Pathol* 2014;45:127-36.
- 54) Yamamoto S, Inoue J, Kawano T, Kozaki K, Omura K, Inazawa J. The impact of miRNA-based molecular diagnostics and treatment of NRF2-stabilized tumors. *Mol Cancer Res* 2014;12:58-68.
- 55) Low SK, Takahashi A, Ashikawa K, Inazawa J, Miki Y, Kubo M, Nakamura Y, Katagiri T. Genome-wide association study of breast cancer in the Japanese population. *PLoS One* 2013;8:e76463.
- 56) Yamamoto Y, Konishi H, Ichikawa D, Arita T, Shoda K, Komatsu S, Shiozaki A, Ikoma H, Fujiwara H, Okamoto K, Ochiai T, Inoue J, Inazawa J, Otsuji E. Significance of GSTP1 for predicting the prognosis and chemotherapeutic efficacy in esophageal squamous cell carcinoma. *Oncol Rep* 2013;30:1687-94.
- 57) Harazono Y, Muramatsu T, Endo H, Uzawa N, Kawano T, Harada K, Inazawa J, Kozaki K. miR-655 is an EMT-suppressive microRNA targeting ZEB1 and TGFBR2. *PLoS One* 2013;8:e62757.
- 58) Furuta M, Kozaki K, Tanimoto K, Tanaka S, Arii S, Shimamura T, Niida A, Miyano S, Inazawa J. The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. *PLoS One* 2013;8:e60155.